SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw a significant gain of 12.3%, closing at $13.19 on July 18, 2026, which increased its estimated equity value to $2.594 billion based on 196.6 million shares outstanding. This marked a $283 million increase in value, despite a noted discrepancy between share counts suggesting a lower market capitalization of $2.275 billion. The company is nearing completion of its REGAL trial, with only two additional required events needed for data unblinding, which is seen as a critical milestone. Additionally, SELLAS’s valuation stands notably higher than its competitors, which have FDA-approved therapies. The stock showed volatility during the week but finished higher compared to the previous Friday. Investors are awaiting further announcements regarding trial outcomes as regular trading resumes on July 20.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://ts2.tech/en/sellas-life-sciences-group-nasdaqsls-surge-draws-attention-to-319-million-market-cap-deficit-ahead-of-regal-trial-results/
